Financing to be conducted by bookrunners Cowen and Piper Jaffray
By Devika Patel
Knoxville, Tenn., June 30 – Syros Pharmaceuticals, Inc. said it priced its $50 million initial public offering of stock with a $7.5 million greenshoe on Tuesday. The deal was announced June 3.
The company will sell 4 million common shares at $12.50 per share.
Cowen and Co., LLC and Piper Jaffray & Co. are the bookrunners. JMP Securities LLC is a lead manager.
Settlement is expected on July 6.
Proceeds will be used for clinical trials, clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs, working capital and other general corporate purposes.
The biopharmaceutical company is based in Cambridge, Mass. The company intends to list its common stock on the Nasdaq under the symbol “SYRS.”
| Issuer: | Syros Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $50 million
|
| Greenshoe: | $7.5 million, or 600,000 shares
|
| Shares: | 4 million
|
| Price: | $12.50
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co., LLC and Piper Jaffray & Co.
|
| Lead manager: | JMP Securities LLC
|
| Co-manager: | Wedbush Securities Inc.
|
| Announcement date: | June 3
|
| Pricing date: | June 30
|
| Settlement date: | July 6
|
| Stock exchange: | Nasdaq: SYRS
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
